Decan,
Re: "Assuming that GBI’s pending pivotal data is equivalent to the Oct 2008 data PapType is in a very strong position to capture a significant % of these markets in the ASCUS/Triage indication…say 30-35%...Sonic Healthcare are also the largest independent pathology provider in Europe"
30-35% seems like a very high assumption. What do you base the percentages on?
Also, what is the likely effect of competition on these percentages, for new tests such as the ones that are being sponsored in relation to the Bill & Melinda Gates foundation program etc. (I can't remember the details, it's late!) and possibly other variants of existing players and new entrants?
Cheers.
- Forums
- ASX - By Stock
- GBI
- why gbi will deliver 10x returns over 12 mths
why gbi will deliver 10x returns over 12 mths, page-24
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GBI (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online